3/13
09:40 am
rnaz
TransCode Therapeutics, Inc. (NASDAQ: RNAZ) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $20.00 price target on the stock.
Medium
Report
TransCode Therapeutics, Inc. (NASDAQ: RNAZ) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $20.00 price target on the stock.
3/13
07:47 am
rnaz
TransCode Therapeutics Announces Safety Review Committee Approval to Open Fourth Cohort in Phase I/II Clinical Trial
High
Report
TransCode Therapeutics Announces Safety Review Committee Approval to Open Fourth Cohort in Phase I/II Clinical Trial
2/25
05:01 pm
rnaz
TransCode Therapeutics, Inc. Announces Results of Special Meeting [Yahoo! Finance]
High
Report
TransCode Therapeutics, Inc. Announces Results of Special Meeting [Yahoo! Finance]
2/25
04:15 pm
rnaz
TransCode Therapeutics, Inc. Announces Results of Special Meeting
High
Report
TransCode Therapeutics, Inc. Announces Results of Special Meeting
2/6
01:31 pm
rnaz
TransCode Therapeutics, Inc. (NASDAQ: RNAZ) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $20.00 price target on the stock.
Low
Report
TransCode Therapeutics, Inc. (NASDAQ: RNAZ) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $20.00 price target on the stock.
2/6
08:00 am
rnaz
TransCode Therapeutics Announces Completion of Cohort 3 Initial Dosing with Lead Candidate in Phase 1 Clinical Trial
High
Report
TransCode Therapeutics Announces Completion of Cohort 3 Initial Dosing with Lead Candidate in Phase 1 Clinical Trial
2/4
04:39 pm
rnaz
TransCode Therapeutics, Inc. Announces Adjournment of Special Meeting and Information for Adjourned Special Meeting [Yahoo! Finance]
High
Report
TransCode Therapeutics, Inc. Announces Adjournment of Special Meeting and Information for Adjourned Special Meeting [Yahoo! Finance]
2/4
04:15 pm
rnaz
TransCode Therapeutics, Inc. Announces Adjournment of Special Meeting and Information for Adjourned Special Meeting
High
Report
TransCode Therapeutics, Inc. Announces Adjournment of Special Meeting and Information for Adjourned Special Meeting
1/14
08:43 am
rnaz
TransCode Therapeutics Announces First Patient Dosed in Third Cohort with Lead Candidate in Phase 1 Clinical Trial [Yahoo! Finance]
Low
Report
TransCode Therapeutics Announces First Patient Dosed in Third Cohort with Lead Candidate in Phase 1 Clinical Trial [Yahoo! Finance]
1/14
08:00 am
rnaz
TransCode Therapeutics Announces First Patient Dosed in Third Cohort with Lead Candidate in Phase 1 Clinical Trial
Medium
Report
TransCode Therapeutics Announces First Patient Dosed in Third Cohort with Lead Candidate in Phase 1 Clinical Trial
1/7
08:20 am
rnaz
Nasdaq Determines That TransCode Therapeutics Has Regained Compliance with Continued Listing Requirements [Yahoo! Finance]
Medium
Report
Nasdaq Determines That TransCode Therapeutics Has Regained Compliance with Continued Listing Requirements [Yahoo! Finance]
1/7
08:10 am
rnaz
TransCode Therapeutics regains compliance with Nasdaq [Seeking Alpha]
Medium
Report
TransCode Therapeutics regains compliance with Nasdaq [Seeking Alpha]
1/7
08:00 am
rnaz
Nasdaq Determines That TransCode Therapeutics Has Regained Compliance with Continued Listing Requirements
Medium
Report
Nasdaq Determines That TransCode Therapeutics Has Regained Compliance with Continued Listing Requirements
12/18
11:49 am
rnaz
TransCode Therapeutics, Inc. (NASDAQ: RNAZ) had its price target raised by analysts at HC Wainwright from $3.00 to $20.00. They now have a "buy" rating on the stock.
Medium
Report
TransCode Therapeutics, Inc. (NASDAQ: RNAZ) had its price target raised by analysts at HC Wainwright from $3.00 to $20.00. They now have a "buy" rating on the stock.
12/18
08:14 am
rnaz
TransCode Therapeutics Announces Safety Review Committee Approval of Opening Third Cohort and Preliminary Results from First Cohort in Phase 1 TTX-MC138 Clinical Trial [Yahoo! Finance]
High
Report
TransCode Therapeutics Announces Safety Review Committee Approval of Opening Third Cohort and Preliminary Results from First Cohort in Phase 1 TTX-MC138 Clinical Trial [Yahoo! Finance]
12/18
08:00 am
rnaz
TransCode Therapeutics Announces Safety Review Committee Approval of Opening Third Cohort and Preliminary Results from First Cohort in Phase 1 TTX-MC138 Clinical Trial
High
Report
TransCode Therapeutics Announces Safety Review Committee Approval of Opening Third Cohort and Preliminary Results from First Cohort in Phase 1 TTX-MC138 Clinical Trial